Colorectal cancer chemoprevention: is aspirin still in the game?

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Katona BW, Weiss JM. Chemoprevention of colorectal cancer. Gastroenterology. 2020;158(2):368–388. doi:10.1053/j.gastro.2019.06.047.
   PubMed Web of Science ®Google Scholar
• Qiao Y, Yang T, Gan Y, Li W, Wang C, Gong Y, Lu Z. Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies. BMC Cancer. 2018;18 doi:10.1186/s12885-018-4156-5.
   Web of Science ®Google Scholar
• Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353(22):2373–2383. doi:10.1056/NEJMra052717.
   PubMed Web of Science ®Google Scholar
• Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol. 2012;9(5):259–267. doi:10.1038/nrclinonc.2011.199.
   PubMed Web of Science ®Google Scholar
• Yan M, Rerko RM, Platzer P, Dawson D, Willis J, Tong M, Lawrence E, Lutterbaugh J, Lu S, Willson JKV, et al. 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-β-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci U S A. 2004;101(50):17468–17473. doi:10.1073/pnas.0406142101.
   PubMed Web of Science ®Google Scholar
• Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 2007;356(21):2131–2142. doi:10.1056/NEJMoa067208.
   PubMed Web of Science ®Google Scholar
• Kuo C-N, Pan -J-J, Huang Y-W, Tsai H-J, Chang W-C. Association between nonsteroidal anti-inflammatory drugs and colorectal cancer: a population-based case–control study. Cancer Epidemiol Biomarkers Prev. 2018;27(7):737–745. doi:10.1158/1055-9965.EPI-17-0876.
   PubMed Web of Science ®Google Scholar
• Mohammed A, Janakiram NB, Madka V, Zhang Y, Singh A, Biddick L, Li Q, Lightfoot S, Steele VE, Lubet RA, et al. Intermittent dosing regimens of aspirin and naproxen inhibit azoxymethane-induced colon adenoma progression to adenocarcinoma and invasive carcinoma. Cancer Prevention Research (Philadelphia, Pa. 2019;12(11):751. doi:10.1158/1940-6207.CAPR-19-0312.
   PubMed Web of Science ®Google Scholar
• Wang D, DuBois RN. Eicosanoids and cancer. Nat Rev Cancer. 2010;10(3):181–193. doi:10.1038/nrc2809.
   PubMed Web of Science ®Google Scholar
• Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994;107(4):1183–1188. doi:10.1016/0016-5085(94)90246-1.
   PubMed Web of Science ®Google Scholar
• Zhang H, Sun X-F. Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer. Am J Gastroenterol. 2002;97(4):1037–1041. doi:10.1111/j.1572-0241.2002.05625.x.
   PubMed Web of Science ®Google Scholar
• Myung S-J, Rerko RM, Yan M, Platzer P, Guda K, Dotson A, Lawrence E, Dannenberg AJ, Lovgren AK, Luo G, et al. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci U S A. 2006;103(32):12098–12102. doi:10.1073/pnas.0603235103.
   PubMed Web of Science ®Google Scholar
• Sheng H, Shao J, Washington MK, DuBois RN. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem. 2001;276(21):18075–18081. doi:10.1074/jbc.M009689200.
   PubMed Web of Science ®Google Scholar
• Wang D, DuBois RN. An inflammatory mediator, prostaglandin E2, in colorectal cancer. Cancer J. 2013;19(6):502–510. doi:10.1097/PPO.0000000000000003.
   PubMed Web of Science ®Google Scholar
• Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol. 2011;6(1):479–507. doi:10.1146/annurev-pathol-011110-130235.
   PubMed Web of Science ®Google Scholar
• Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a G s -Axin-ß-catenin signaling axis. Science. 2005;310(5753):1504–1510. doi:10.1126/science.1116221.
   PubMed Web of Science ®Google Scholar
• Goessling W, North TE, Loewer S, Lord AM, Lee S, Stoick-Cooper CL, Weidinger G, Puder M, Daley GQ, Moon RT, et al. Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell. 2009;136(6):1136–1147. doi:10.1016/j.cell.2009.01.015.
   PubMed Web of Science ®Google Scholar
• Wang D, Wang H, Shi Q, Katkuri S, Walhi W, Desvergne B, Das SK, Dey SK, DuBois RN. Prostaglandin E2 promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor δ. Cancer Cell. 2004;6(3):285–295. doi:10.1016/j.ccr.2004.08.011.
   PubMed Web of Science ®Google Scholar
• Gupta RA, Wang D, Katkuri S, Wang H, Dey SK, DuBois RN. Activation of nuclear hormone receptor peroxisome proliferator–activated receptor-δ accelerates intestinal adenoma growth. Nat Med. 2004;10(3):245–247. doi:10.1038/nm993.
   PubMed Web of Science ®Google Scholar
• He T-C, Chan TA, Vogelstein B, Kinzler KW. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell. 1999;99(3):335–345. doi:10.1016/S0092-8674(00)81664-5.
   PubMed Web of Science ®Google Scholar
• Smartt HJM, Greenhough A, Ordóñez-Morán P, Talero E, Cherry CA, Wallam CA, Parry L, Al Kharusi M, Roberts HR, Mariadason JM, et al. β-catenin represses expression of the tumour suppressor 15-prostaglandin dehydrogenase in the normal intestinal epithelium and colorectal tumour cells. Gut. 2012;61(9):1306–1314. doi:10.1136/gutjnl-2011-300817.
   PubMed Web of Science ®Google Scholar
• Gala MK, Chan AT. Molecular pathways: aspirin and wnt signaling—a molecularly targeted approach to cancer prevention and treatment. Clin Cancer Res. 2015;21(7):1543–1548. doi:10.1158/1078-0432.CCR-14-0877.
   PubMed Web of Science ®Google Scholar
• Drew DA, Cao Y, Chan AT. Aspirin and colorectal cancer: the promise of precision chemoprevention. Nat Rev Cancer. 2016;16(3):173–186. doi:10.1038/nrc.2016.4.
   PubMed Web of Science ®Google Scholar
• Bos CL, Kodach LL, van den Brink GR, Diks SH, van Santen MM, Richel DJ, Peppelenbosch MP, Hardwick JCH. Effect of aspirin on the Wnt/β-catenin pathway is mediated via protein phosphatase 2A. Oncogene. 2006;25(49):6447–6456. doi:10.1038/sj.onc.1209658.
   PubMed Web of Science ®Google Scholar
• Buchanan FG, Gorden DL, Matta P, Shi Q, Matrisian LM, DuBois RN. Role of β-arrestin 1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci U S A. 2006;103(5):1492–1497. doi:10.1073/pnas.0510562103.
   PubMed Web of Science ®Google Scholar
• Buchanan FG, Wang D, Bargiacchi F, DuBois RN. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem. 2003;278(37):35451–35457. doi:10.1074/jbc.M302474200.
   PubMed Web of Science ®Google Scholar
• Zumwalt TJ, Wodarz D, Komarova NL, Toden S, Turner J, Cardenas J, Burn J, Chan AT, Boland CR, Goel A. Aspirin-induced chemoprevention and response kinetics are enhanced by PIK3CA mutations in colorectal cancer cells. Cancer Prev Res (Phila). 2017;10(3):208–218. doi:10.1158/1940-6207.CAPR-16-0175.
   PubMed Web of Science ®Google Scholar
• Gu M, Nishihara R, Chen Y, Li W, Shi Y, Masugi Y, Hamada T, Kosumi K, Liu L, da Silva A, et al. Aspirin exerts high anti-cancer activity in PIK3CA -mutant colon cancer cells. Oncotarget. 2017;8(50):87379–87389. doi:10.18632/oncotarget.20972.
   PubMedGoogle Scholar
• Wang D, Buchanan FG, Wang H, Dey SK, DuBois RN. Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res. 2005;65(5):1822–1829. doi:10.1158/0008-5472.CAN-04-3671.
   PubMed Web of Science ®Google Scholar
• Pan M-R, Chang H-C, Hung W-C. Non-steroidal anti-inflammatory drugs suppress the ERK signaling pathway via block of Ras/c-Raf interaction and activation of MAP kinase phosphatases. Cell Signal. 2008;20(6):1134–1141. doi:10.1016/j.cellsig.2008.02.004.
   PubMed Web of Science ®Google Scholar
• Yin M-J, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β. Nature. 1998;396(6706):77–80. doi:10.1038/23948.
   PubMed Web of Science ®Google Scholar
• Dovizio M, Bruno A, Tacconelli S, Patrignani P. Mode of action of aspirin as a chemopreventive agent. Recent Results Cancer Res. 2013;191:39–65.
   PubMedGoogle Scholar
• Ying J, Zhou H, Liu P, You Q, Kuang F, Shen Y, Hu Z. Aspirin inhibited the metastasis of colon cancer cells by inhibiting the expression of toll-like receptor 4. Cell Biosci. 2018;8(1). doi:10.1186/s13578-017-0198-7.
   PubMedGoogle Scholar
• Jung YR, Kim EJ, Choi HJ, Park -J-J, Kim H-S, Lee Y-J, Park M-J, Lee M. Aspirin targets SIRT1 and AMPK to induce senescence of colorectal carcinoma cells. Mol Pharmacol. 2015;88(4):708–719. doi:10.1124/mol.115.098616.
   PubMed Web of Science ®Google Scholar
• Din FVN, Valanciute A, Houde VP, Zibrova D, Green KA, Sakamoto K, Alessi DR, Dunlop MG. Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology. 2012;142(7):1504–15.e3. doi:10.1053/j.gastro.2012.02.050.
   PubMed Web of Science ®Google Scholar
• Zimmermann KC, Waterhouse NJ, Goldstein JC, Schuler M, Green DR. Aspirin induces apoptosis through release of cytochrome c from mitochondria. Neoplasia. 2000;2(6):505–513. doi:10.1038/sj.neo.7900120.
   PubMed Web of Science ®Google Scholar
• Gu Q, Wang JD, Xia HHX, Lin MCM, He H, Zou B, Tu SP, Yang Y, Liu XG, Lam SK, et al. Activation of the caspase-8/Bid and Bax pathways in aspirin-induced apoptosis in gastric cancer. Carcinogenesis. 2005;26(3):541–546. doi:10.1093/carcin/bgh345.
   PubMed Web of Science ®Google Scholar
• Wang Y, Du C, Zhang N, Li M, Liu Y, Zhao M, Wang F, Luo F. TGF-β1 mediates the effects of aspirin on colonic tumor cell proliferation and apoptosis. Oncol Lett. 2018;15(4):5903–5909. doi:10.3892/ol.2018.8047.
   PubMed Web of Science ®Google Scholar
• Dovizio M, Maier TJ, Alberti S, Di Francesco L, Marcantoni E, Münch G, John CM, Suess B, Sgambato A, Steinhilber D, et al. Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells. Mol Pharmacol. 2013;84(1):25–40. doi:10.1124/mol.113.084988.
   PubMed Web of Science ®Google Scholar
• Patrono C. The multifaceted clinical readouts of platelet inhibition by low-dose aspirin. J Am Coll Cardiol. 2015;66(1):74–85. doi:10.1016/j.jacc.2015.05.012.
   PubMed Web of Science ®Google Scholar
• Boutaud O, Sosa IR, Amin T, Oram D, Adler D, Hwang HS, Crews BC, Milne G, Harris BK, Hoeksema M, et al. Inhibition of the biosynthesis of prostaglandin E2 by low-dose aspirin: implications for adenocarcinoma metastasis. Cancer Prev Res (Phila). 2016;9(11):855–865. doi:10.1158/1940-6207.CAPR-16-0094.
   PubMed Web of Science ®Google Scholar
• Mitrugno A, Sylman JL, Ngo ATP, Pang J, Sears RC, Williams CD, McCarty OJT. Aspirin therapy reduces the ability of platelets to promote colon and pancreatic cancer cell proliferation: implications for the oncoprotein c-MYC. Am J Physiol Cell Physiol. 2017;312(2):C176–89. doi:10.1152/ajpcell.00196.2016.
   PubMed Web of Science ®Google Scholar
• Xu XR, Yousef GM, Ni H. Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents. Blood. 2018;131(16):1777–1789. doi:10.1182/blood-2017-05-743187.
   PubMed Web of Science ®Google Scholar
• Kopp H-G, Placke T, Salih HR. Platelet-derived transforming growth factor-β down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res. 2009;69(19):7775–7783. doi:10.1158/0008-5472.CAN-09-2123.
   PubMed Web of Science ®Google Scholar
• Placke T, Örgel M, Schaller M, Jung G, Rammensee H-G, Kopp H-G, Salih HR. Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res. 2012;72(2):440–448. doi:10.1158/0008-5472.CAN-11-1872.
   PubMed Web of Science ®Google Scholar
• Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011;11(2):123–134. doi:10.1038/nrc3004.
   PubMed Web of Science ®Google Scholar
• Schumacher D, Strilic B, Sivaraj KK, Wettschureck N, Offermanns S. Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell. 2013;24(1):130–137. doi:10.1016/j.ccr.2013.05.008.
   PubMed Web of Science ®Google Scholar
• Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20(5):576–590. doi:10.1016/j.ccr.2011.09.009.
   PubMed Web of Science ®Google Scholar
• Guillem-Llobat P, Dovizio M, Bruno A, Ricciotti E, Cufino V, Sacco A, Grande R, Alberti S, Arena V, Cirillo M, et al. Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells. Oncotarget. 2016;7(22):32462–32477. doi:10.18632/oncotarget.8655.
   PubMedGoogle Scholar
• Schottenfeld D, Beebe-Dimmer J. Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin. 2006;56(2):69–83. doi:10.3322/canjclin.56.2.69.
   PubMed Web of Science ®Google Scholar
• Aoki T, Narumiya S. Prostaglandin E2-EP2 signaling as a node of chronic inflammation in the colon tumor microenvironment. Inflammation and Regeneration. 2017;37(1). doi:10.1186/s41232-017-0036-7.
   PubMedGoogle Scholar
• Ma X, Aoki T, Tsuruyama T, Narumiya S. Definition of prostaglandin E2–EP2 signals in the colon tumor microenvironment that amplify inflammation and tumor growth. Cancer Res. 2015;75(14):2822–2832. doi:10.1158/0008-5472.CAN-15-0125.
   PubMed Web of Science ®Google Scholar
• Mizuno R, Kawada K, Sakai Y. Prostaglandin E2/EP signaling in the tumor microenvironment of colorectal cancer. Int J Mol Sci. 2019;20(24):6254. doi:10.3390/ijms20246254.
   Web of Science ®Google Scholar
• Wang D, DuBois RN. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene. 2010;29(6):781–788. doi:10.1038/onc.2009.421.
   PubMed Web of Science ®Google Scholar
• Yao C, Sakata D, Esaki Y, Li Y, Matsuoka T, Kuroiwa K, Sugimoto Y, Narumiya S. Prostaglandin E2–EP4 signaling promotes immune inflammation through TH1 cell differentiation and TH17 cell expansion. Nat Med. 2009;15(6):633–640. doi:10.1038/nm.1968.
   PubMed Web of Science ®Google Scholar
• Sheibanie AF, Yen J-H, Khayrullina T, Emig F, Zhang M, Tuma R, Ganea D. The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23→IL-17 axis. J Immunol. 2007;178(12):8138–8147. doi:10.4049/jimmunol.178.12.8138.
   PubMed Web of Science ®Google Scholar
• Scandella E, Men Y, Gillessen S, Förster R, Groettrup M. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood. 2002;100(4):1354–1361. doi:10.1182/blood-2001-11-0017.
   PubMed Web of Science ®Google Scholar
• Stryker SJ, Wolff BG, Culp CE, Libbe SD, Ilstrup DM, MacCarty RL. Natural history of untreated colonic polyps. Gastroenterology. 1987;93(5):1009–1013. doi:10.1016/0016-5085(87)90563-4.
   PubMed Web of Science ®Google Scholar
• Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348(10):883–890. doi:10.1056/NEJMoa021633.
   PubMed Web of Science ®Google Scholar
• Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348(10):891–899. doi:10.1056/NEJMoa021735.
   PubMed Web of Science ®Google Scholar
• Logan RFA, Grainge MJ, Shepherd VC, Armitage NC, Muir KR, ukCAP Trial Group. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology. 2008;134(1):29–38. 10.1053/j.gastro.2007.10.014
   PubMed Web of Science ®Google Scholar
• Benamouzig R, Uzzan B, Deyra J, Martin A, Girard B, Little J, Chaussade S, Association pour la Prévention par l’Aspirine du Cancer Colorectal Study Group (APACC). Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year results of the APACC randomised trial. Gut. 2012;61(2):255–261. 10.1136/gutjnl-2011-300113
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Mutoh M, Suzuki S, Tokudome S, Saida Y, Abe T, Okamura S, Tajika M, Joh T, Tanaka S, et al. The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial. Gut. 2014;63(11):1755–1759. doi:10.1136/gutjnl-2013-305827.
   PubMed Web of Science ®Google Scholar
• Pommergaard H-C, Burcharth J, Rosenberg J, Raskov H. Aspirin, calcitriol, and calcium do not prevent adenoma recurrence in a randomized controlled trial. Gastroenterology. 2016;150(1):114–122.e4. doi:10.1053/j.gastro.2015.09.010.
   PubMed Web of Science ®Google Scholar
• Hull MA, Sprange K, Hepburn T, Tan W, Shafayat A, Rees CJ, Clifford G, Logan RF, Loadman PM, Williams EA, et al. Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial. Lancet. 2018;392(10164):2583–2594. doi:10.1016/S0140-6736(18)31775-6.
   PubMed Web of Science ®Google Scholar
• Veettil SK, Lim KG, Ching SM, Saokaew S, Phisalprapa P, Chaiyakunapruk N. Effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs on the incidence of recurrent colorectal adenomas: a systematic review with meta-analysis and trial sequential analysis of randomized clinical trials. BMC Cancer. 2017;17(1). doi:10.1186/s12885-017-3757-8.
   PubMedGoogle Scholar
• Higurashi T, Hosono K, Takahashi H, Komiya Y, Umezawa S, Sakai E, Uchiyama T, Taniguchi L, Hata Y, Uchiyama S, et al. Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. Lancet Oncol. 2016;17(4):475–483. doi:10.1016/S1470-2045(15)00565-3.
   PubMed Web of Science ®Google Scholar
• Friis S, Riis AH, Erichsen R, Baron JA, Sørensen HT. Low-dose aspirin or nonsteroidal anti-inflammatory drug use and colorectal cancer risk: a population-based, case-control study. Ann Intern Med. 2015;163(5):347–355. doi:10.7326/M15-0039.
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Wilson M, Elwin C-E, Norrving B, Algra A, Warlow CP, Meade TW. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376(9754):1741–1750. doi:10.1016/S0140-6736(10)61543-7.
   PubMed Web of Science ®Google Scholar
• García Rodríguez LA, Soriano-Gabarró M, Bromley S, Lanas A, Cea Soriano L. New use of low-dose aspirin and risk of colorectal cancer by stage at diagnosis: a nested case–control study in UK general practice. BMC Cancer. 2017;17(1). doi:10.1186/s12885-017-3594-9.
   PubMedGoogle Scholar
• Stürmer T, Glynn RJ, Lee IM, Manson JE, Buring JE, Hennekens CH. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians’ Health Study. Ann Intern Med. 1998;128(9):713–720. doi:10.7326/0003-4819-128-9-199805010-00003.
   PubMed Web of Science ®Google Scholar
• Cook NR, Lee I-M, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE. Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. JAMA. 2005;294(1):47–55. doi:10.1001/jama.294.1.47.
   PubMed Web of Science ®Google Scholar
• Cook NR, Lee I-M, Zhang SM, Moorthy MV, Buring JE. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med. 2013;159(2):77–85. doi:10.7326/0003-4819-159-2-201307160-00002.
   PubMed Web of Science ®Google Scholar
• McNeil JJ, Nelson MR, Woods RL, Lockery JE, Wolfe R, Reid CM, Kirpach B, Shah RC, Ives DG, Storey E, et al. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med. 2018;379(16):1519–1528. doi:10.1056/NEJMoa1803955.
   PubMed Web of Science ®Google Scholar
• Chan AT, Ladabaum U. Where do we stand with aspirin for the prevention of colorectal cancer? The USPSTF recommendations. Gastroenterology. 2016;150(1):14–18. doi:10.1053/j.gastro.2015.11.018.
   PubMed Web of Science ®Google Scholar
• Burn J, Bishop DT, Chapman PD, Elliott F, Bertario L, Dunlop MG, Eccles D, Ellis A, Evans DG, Fodde R, et al. A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila). 2011;4(5):655–665. doi:10.1158/1940-6207.CAPR-11-0106.
   PubMed Web of Science ®Google Scholar
• Burn J, Gerdes A-M, Macrae F, Mecklin J-P, Moeslein G, Olschwang S, Eccles D, Evans DG, Maher ER, Bertario L, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011;378(9809):2081–2087. doi:10.1016/S0140-6736(11)61049-0.
   PubMed Web of Science ®Google Scholar
• Burn J, Sheth H, Elliott F, Reed L, Macrae F, Mecklin J-P, Möslein G, McRonald FE, Bertario L, Evans DG, et al. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lancet. 2020;395(10240):1855–1863. doi:10.1016/S0140-6736(20)30366-4.
   PubMed Web of Science ®Google Scholar
• Burn J, Mathers JC, Bishop DT. Chemoprevention in Lynch syndrome. Fam Cancer. 2013;12(4):707–718. doi:10.1007/s10689-013-9650-y.
   PubMed Web of Science ®Google Scholar
• Effect of chemoprevention by low-dose aspirin of new or recurrent colorectal adenomas in patients with lynch syndrome - full text view - ClinicalTrials.gov; 2020. [accedded 2020 Apr 30 https://clinicaltrials.gov/ct2/show/NCT02813824.
   Google Scholar
• Chan AT. Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 2009;302(6):649–658. doi:10.1001/jama.2009.1112.
   PubMed Web of Science ®Google Scholar
• Restivo A, Cocco IMF, Casula G, Scintu F, Cabras F, Scartozzi M, Zorcolo L. Aspirin as a neoadjuvant agent during preoperative chemoradiation for rectal cancer. Br J Cancer. 2015;113(8):1133–1139. doi:10.1038/bjc.2015.336.
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. The Lancet. 2012;379(9826):1591–1601. doi:10.1016/S0140-6736(12)60209-8.
   PubMed Web of Science ®Google Scholar
• Yang L, Lv Z, Xia W, Zhang W, Xin Y, Yuan H, Chen Y, Hu X, Lv Y, Xu Q, et al. The effect of aspirin on circulating tumor cells in metastatic colorectal and breast cancer patients: a phase II trial study. Clin Transl Oncol. 2018;20(7):912–921. doi:10.1007/s12094-017-1806-z.
   PubMed Web of Science ®Google Scholar
• Li P, Wu H, Zhang H, Shi Y, Xu J, Ye Y, Xia D, Yang J, Cai J, Wu Y. Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis. Gut. 2015;64(9):1419–1425. doi:10.1136/gutjnl-2014-308260.
   PubMed Web of Science ®Google Scholar
• Bastiaannet E, Sampieri K, Dekkers OM, de Craen AJM, van Herk-sukel MPP, Lemmens V, van den Broek CBM, Coebergh JW, Herings RMC, van de Velde CJH, et al. Use of aspirin postdiagnosis improves survival for colon cancer patients. Br J Cancer. 2012;106(9):1564–1570. doi:10.1038/bjc.2012.101.
   PubMed Web of Science ®Google Scholar
• McCowan C, Munro AJ, Donnan PT, Steele RJC. Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality. Eur J Cancer. 2013;49(5):1049–1057. doi:10.1016/j.ejca.2012.10.024.
   PubMed Web of Science ®Google Scholar
• Goh CH, Goh HH, Leong WQ, Chew MH, Pan YS, Tony LKH, Chew L, Tan IBH, Toh HC, Tang CL, et al. Post-operative aspirin use and colorectal cancer-specific survival in patients with stage I-III colorectal cancer. Anticancer Res. 2014;34(12):7407–7414.
   PubMed Web of Science ®Google Scholar
• Bains SJ, Mahic M, Myklebust TÅ, Småstuen MC, Yaqub S, Dørum LM, Bjørnbeth BA, Møller B, Brudvik KW, Taskén K. Aspirin as secondary prevention in patients with colorectal cancer: an unselected population-based study. J Clin Oncol. 2016;34(21):2501–2508. doi:10.1200/JCO.2015.65.3519.
   PubMed Web of Science ®Google Scholar
• Cardwell CR, Kunzmann AT, Cantwell MM, Hughes C, Baron JA, Powe DG, Murray LJ. Low-dose aspirin use after diagnosis of colorectal cancer does not increase survival: a case–control analysis of a population-based cohort. Gastroenterology. 2014;146(3):700–708.e2. doi:10.1053/j.gastro.2013.11.005.
   PubMed Web of Science ®Google Scholar
• Gray RT, Coleman HG, Hughes C, Murray LJ, Cardwell CR. Low-dose aspirin use and survival in colorectal cancer: results from a population-based cohort study. BMC Cancer. 2018;18(1):228. doi:10.1186/s12885-018-4142-y.
   PubMedGoogle Scholar
• Ali R, Toh H-C, Chia W-K. The utility of Aspirin in dukes C and high risk dukes B colorectal cancer - The ASCOLT study: study protocol for a randomized controlled trial. Trials. 2011;12(1):261. doi:10.1186/1745-6215-12-261.
   PubMed Web of Science ®Google Scholar
• Michel P, Boige V, Andre T, Aparicio T, Bachet JB, Dahan L, Guimbaud R, Lepage C, Manfredi S, Tougeron D, et al. Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: a French randomised double-blind phase III trial (PRODIGE 50-ASPIK). Dig Liver Dis. 2018;50(3):305–307. doi:10.1016/j.dld.2017.12.023.
   PubMedGoogle Scholar
• Aspirin for prevention of postsurgical recurrence and metastasis in asian colorectal cancer patients: a multi-center randomized trial - full text view - ClinicalTrials.gov; 2020. [cited 2020 Apr 30]. https://clinicaltrials.gov/ct2/show/NCT02607072.
   Google Scholar
• Coyle C, Cafferty FH, Rowley S, MacKenzie M, Berkman L, Gupta S, Pramesh CS, Gilbert D, Kynaston H, Cameron D, et al. ADD-ASPIRIN: a phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. Contemp Clin Trials. 2016;51:56–64. doi:10.1016/j.cct.2016.10.004.
   PubMed Web of Science ®Google Scholar
• Nan H, Hutter CM, Lin Y, Jacobs EJ, Ulrich CM, White E, Baron JA, Berndt SI, Brenner H, Butterbach K, et al. Association of Aspirin and NSAID use with risk of colorectal cancer according to genetic variants. JAMA. 2015;313(11):1133–1142. doi:10.1001/jama.2015.1815.
   PubMed Web of Science ®Google Scholar
• Nan H, Morikawa T, Suuriniemi M, Imamura Y, Werner L, Kuchiba A, Yamauchi M, Hunter DJ, Kraft P, Giovannucci EL, et al. Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations. J Natl Cancer Inst. 2013;105(24):1852–1861. doi:10.1093/jnci/djt331.
   PubMed Web of Science ®Google Scholar
• Resler AJ, Makar KW, Heath L, Whitton J, Potter JD, Poole EM, Habermann N, Scherer D, Duggan D, Wang H, et al. Genetic variation in prostaglandin synthesis and related pathways, NSAID use and colorectal cancer risk in the Colon Cancer Family Registry. Carcinogenesis. 2014;35(9):2121–2126. doi:10.1093/carcin/bgu119.
   PubMed Web of Science ®Google Scholar
• Hubner RA, Muir KR, Liu J-F, Logan RFA, Grainge MJ, Houlston RS. Members of the UKCAP Consortium. Ornithine decarboxylase G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention. Clin Cancer Res. 2008;14(8):2303–2309. doi:10.1158/1078-0432.CCR-07-4599.
   PubMed Web of Science ®Google Scholar
• Barry EL, Mott LA, Sandler RS, Ahnen DJ, Baron JA. Variants downstream of the ornithine decarboxylase gene influence risk of colorectal adenoma and Aspirin Chemoprevention. Cancer Prev Res (Phila). 2011;4(12):2072–2082. doi:10.1158/1940-6207.CAPR-11-0300.
   PubMed Web of Science ®Google Scholar
• Gray RT, Cantwell MM, Coleman HG, Loughrey MB, Bankhead P, McQuaid S, O’Neill RF, Arthur K, Bingham V, McGready C, et al. Evaluation of PTGS2 expression, PIK3CA mutation, aspirin use and colon cancer survival in a population-based cohort study. Clin Transl Gastroenterol. 2017;8(4):e91. doi:10.1038/ctg.2017.18.
   PubMedGoogle Scholar
• Shrubsole MJ, Cai Q, Wen W, Milne G, Smalley WE, Chen Z, Ness RM, Zheng W. Urinary prostaglandin E2 metabolite and risk for colorectal adenoma. Cancer Prev Res (Phila). 2012;5(2):336–342. doi:10.1158/1940-6207.CAPR-11-0426.
   PubMed Web of Science ®Google Scholar
• Bezawada N, Song M, Wu K, Mehta RS, Milne GL, Ogino S, Fuchs CS, Giovannucci EL, Chan AT. Urinary PGE-M levels are associated with risk of colorectal adenomas and chemopreventive response to anti-inflammatory drugs. Cancer Prev Res (Phila). 2014;7(7):758–765. doi:10.1158/1940-6207.CAPR-14-0120.
   PubMed Web of Science ®Google Scholar
• Fink SP, Yamauchi M, Nishihara R, Jung S, Kuchiba A, Wu K, Cho E, Giovannucci E, Fuchs CS, Ogino S, et al. Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD). Sci Transl Med. 2014;6(233):233re2. doi:10.1126/scitranslmed.3008481.
   PubMed Web of Science ®Google Scholar
• Fink SP, Yang D-H, Barnholtz-Sloan JS, Ryu Y-M, Mikkola D, Potter JD, Lampe JW, Markowitz SD, Myung S-J. Colonic 15-PGDH levels are stable across distance and time and are not perturbed by aspirin intervention. Dig Dis Sci. 2013;58(9):2615–2622. doi:10.1007/s10620-013-2670-5.
   PubMed Web of Science ®Google Scholar
• Nishihara R, Lochhead P, Kuchiba A, Jung S, Yamauchi M, Liao X, Imamura Y, Qian ZR, Morikawa T, Wang M, et al. Aspirin use and risk of colorectal cancer according to braf mutation status. JAMA. 2013;309(24):2563–2571. doi:10.1001/jama.2013.6599.
   PubMed Web of Science ®Google Scholar
• Hua X, Phipps AI, Burnett-Hartman AN, Adams SV, Hardikar S, Cohen SA, Kocarnik JM, Ahnen DJ, Lindor NM, Baron JA, et al. Timing of aspirin and other nonsteroidal anti-inflammatory drug use among patients with colorectal cancer in relation to tumor markers and survival. J Clin Oncol. 2017;35(24):2806–2813. doi:10.1200/JCO.2017.72.3569.
   PubMed Web of Science ®Google Scholar
• Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012;367(17):1596–1606. doi:10.1056/NEJMoa1207756.
   PubMed Web of Science ®Google Scholar
• Domingo E, Church DN, Sieber O, Ramamoorthy R, Yanagisawa Y, Johnstone E, Davidson B, Kerr DJ, Tomlinson IPM, Midgley R. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol. 2013;31(34):4297–4305. doi:10.1200/JCO.2013.50.0322.
   PubMed Web of Science ®Google Scholar
• Reimers MS, Bastiaannet E, Langley RE, van Eijk R, van Vlierberghe RLP, Lemmens VEP, van Herk-sukel MPP, van Wezel T, Fodde R, Kuppen PJK, et al. Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer. JAMA Intern Med. 2014;174(5):732–739. doi:10.1001/jamainternmed.2014.511.
   PubMed Web of Science ®Google Scholar
• Kothari N, Kim R, Jorissen RN, Desai J, Tie J, Wong H-L, Farragher I, Jones I, Day FL, LI S, et al. Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation. Acta Oncol. 2015;54(4):487–492. doi:10.3109/0284186X.2014.990158.
   PubMed Web of Science ®Google Scholar
• Murphy C, Turner N, Wong H-L, Sinnathamby M, Tie J, Lee B, Desai J, Skinner I, Christie M, Hutchinson R, et al. Examining the impact of regular aspirin use and PIK3CA mutations on survival in stage 2 colon cancer. Intern Med J. 2017;47(1):88–98. doi:10.1111/imj.13312.
   PubMed Web of Science ®Google Scholar
• Faivre J, Dancourt V, Lejeune C, Tazi MA, Lamour J, Gerard D, Dassonville F, Bonithon-Kopp C. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology. 2004;126(7):1674–1680. doi:10.1053/j.gastro.2004.02.018.
   PubMed Web of Science ®Google Scholar
• Brenner H, Calderazzo S, Seufferlein T, Ludwig L, Dikopoulos N, Mangold J, Böck W, Stolz T, Eisenbach T, Block T, et al. Effect of a single aspirin dose prior to fecal immunochemical testing on test sensitivity for detecting advanced colorectal neoplasms. JAMA. 2019;321(17):1686–1692. doi:10.1001/jama.2019.4755.
   PubMed Web of Science ®Google Scholar
• Randel KR, Botteri E, Romstad KMK, Frigstad SO, Bretthauer M, Hoff G, de Lange T, Holme Ø. Effects of oral anticoagulants and aspirin on performance of fecal immunochemical tests in colorectal cancer screening. Gastroenterology. 2019;156(6):1642–1649.e1. doi:10.1053/j.gastro.2019.01.040.
   PubMed Web of Science ®Google Scholar
• Nieuwenburg SAV, Vuik FER, Kruip MJHA, Kuipers EJ, Spaander MCW. Effect of anticoagulants and NSAIDs on accuracy of faecal immunochemical tests (FITs) in colorectal cancer screening: a systematic review and meta-analysis. Gut. 2019;68(5):866–872. doi:10.1136/gutjnl-2018-316344.
   PubMed Web of Science ®Google Scholar
• Robertson DJ, Lee JK, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, Lieberman D, Levin TR, Rex DK. Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US multi-society task force on colorectal cancer. Gastroenterology. 2017;152(5):1217–1237.e3. doi:10.1053/j.gastro.2016.08.053.
   PubMed Web of Science ®Google Scholar
• Tsoi KK, Chan FC, Hirai HW, Sung JJ. Risk of gastrointestinal bleeding and benefit from colorectal cancer reduction from long-term use of low-dose aspirin: a retrospective study of 612 509 patients. J Gastroenterol Hepatol. 2018;33(10):1728–1736. doi:10.1111/jgh.14261.
   PubMed Web of Science ®Google Scholar
• Lanas A, Wu P, Medin J, Mills EJ. Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis. Clinical Gastroenterology and Hepatology. 2011;9(9):762–768.e6. doi:10.1016/j.cgh.2011.05.020.
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Baggish JS, Bhatt DL, Topol EJ. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol. 2005;95(10):1218–1222. doi:10.1016/j.amjcard.2005.01.049.
   PubMed Web of Science ®Google Scholar